What it's for (Indications)
- Quatrefolate, as a biologically active form of folate (specifically, (6S)-5-methyltetrahydrofolate or 5-MTHF), is indicated for the dietary management of distinct nutritional requirements associated with conditions responsive to increased folate levels.
- This primarily includes individuals with compromised folate metabolism due to genetic variations, such as methylenetetrahydrofolate reductase (MTHFR) polymorphisms, which impair the conversion of synthetic folic acid to its active form.
- It is particularly relevant for the prevention of neural tube defects during pregnancy, for supporting healthy homocysteine levels, and in conditions where folate deficiency may contribute to symptoms like fatigue, mood disturbances, or impaired cognitive function.
- Its use ensures effective folate utilization, bypassing common metabolic obstacles.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of quatrefolate should be individualized based on the patient's specific nutritional needs, medical condition, and response to therapy. Standard doses typically range from 0.4 mg to 15 mg daily, often administered orally. For general folate supplementation, especially in preconception and prenatal care to reduce the risk of neural tube defects, a daily dose of 0.4 mg to 1 mg is common. In cases of diagnosed folate deficiency or genetic polymorphisms affecting folate metabolism, higher doses, such as 7.5 mg or 15 mg, may be prescribed under medical supervision. It is crucial for healthcare providers to assess the patient's MTHFR status and other clinical factors to determine the optimal therapeutic regimen. Dosing regimens should always adhere to the prescribing information of specific formulations. |
Safety & Warnings
Common Side Effects
- Quatrefolate is generally well-tolerated at recommended dosages, with a low incidence of adverse effects.
- Most reported side effects are mild and transient.
- These may include gastrointestinal disturbances such as nausea, abdominal discomfort, or diarrhea.
- Dermatological reactions like rash or pruritus are rare.
- In some sensitive individuals, particularly at higher doses, central nervous system effects such as irritability, sleep disturbances, or overstimulation have been reported, although these are uncommon.
- It is important to differentiate between actual adverse drug reactions and symptoms that might be indicative of underlying medical conditions.
- Any persistent or severe side effects should be reported to a healthcare professional for evaluation.
- Patients should be advised not to exceed prescribed doses without medical consultation.
Serious Warnings
- Black Box Warning: **Serious Warnings:** Quatrefolate, as an active folate, does not carry a specific Black Box Warning issued by regulatory bodies such as the FDA. However, a significant cautionary note, akin to a serious warning, pertains to its potential to mask vitamin B12 deficiency. Administering folate, including quatrefolate, to patients with undiagnosed or untreated pernicious anemia (vitamin B12 deficiency) can correct the megaloblastic anemia, a hematological symptom, while allowing the irreversible neurological damage associated with vitamin B12 deficiency to progress unchecked. This can lead to severe and permanent neurological impairment. Therefore, before initiating high-dose quatrefolate therapy, especially in elderly patients or those at risk for vitamin B12 deficiency, it is critically important to accurately diagnose and rule out vitamin B12 deficiency. If vitamin B12 deficiency is confirmed or suspected, concomitant vitamin B12 supplementation must be administered. Failure to adhere to this precaution can result in severe adverse patient outcomes.
- While quatrefolate is generally safe, several warnings warrant consideration.
- Patients with a history of seizures should use folate derivatives cautiously, as high doses may potentially exacerbate seizure activity in some individuals, particularly those receiving anti-epileptic medications.
- Folate supplementation, including quatrefolate, can mask the hematological manifestations of vitamin B12 deficiency (pernicious anemia) while allowing neurological damage to progress irreversibly.
- Therefore, it is imperative to rule out vitamin B12 deficiency prior to initiating high-dose folate therapy, or to administer folate concurrently with vitamin B12.
- Individuals with known hypersensitivity to folate or any component of the formulation should avoid its use.
- Caution is advised in patients with bipolar disorder, as high doses of folate might trigger manic episodes in susceptible individuals.
- Always consult a healthcare professional before starting or altering any folate supplementation regimen.
How it Works (Mechanism of Action)
Quatrefolate ((6S)-5-methyltetrahydrofolate, or 5-MTHF) is the most metabolically active and bioavailable form of folate, serving as the primary circulating form in the body that crosses the blood-brain barrier. Unlike synthetic folic acid, quatrefolate does not require enzymatic reduction by dihydrofolate reductase (DHFR) to become metabolically active. This direct bioavailability is particularly advantageous for individuals with genetic polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, which can impair the body's ability to convert folic acid to 5-MTHF. As a coenzyme, 5-MTHF plays a critical role in one-carbon metabolism, including methylation reactions and the synthesis of DNA, RNA, and proteins. It is essential for the conversion of homocysteine to methionine, a crucial step in maintaining cardiovascular health and neurotransmitter synthesis. Its direct delivery ensures efficient participation in these vital metabolic pathways.